Last reviewed · How we verify
Auto-hMSCs
At a glance
| Generic name | Auto-hMSCs |
|---|---|
| Sponsor | University of Miami |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Weight increased
- Mitral valve incompetence
- Upper respiratory tract infection
- Dyspnoea
- Wheezing
- Anemia
- Ventricular tachycardia
- Adverse drug reaction
- Chest Discomfort
- Vulvovaginal mycotic infection
- Electrocardiogram abnormal
- Dizziness
Key clinical trials
- PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study) (PHASE1, PHASE2)
- The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Auto-hMSCs CI brief — competitive landscape report
- Auto-hMSCs updates RSS · CI watch RSS
- University of Miami portfolio CI